MCID: LNG032
MIFTS: 99

Lung Cancer

Categories: Genetic diseases, Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer

MalaCards integrated aliases for Lung Cancer:

Name: Lung Cancer 53 12 72 24 71 28 40 3 14
Non-Small Cell Lung Carcinoma 37 12 14 69
Non-Small Cell Lung Cancer 12 72 36 28
Lung Carcinoma 12 51 14
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 53 13
Nonsmall Cell Lung Cancer, Somatic 53 13
Lung Cancer, Protection Against 53 28
Malignant Neoplasm of Lung 24 69
Nonsmall Cell Lung Cancer 53 71
Alveolar Cell Carcinoma 71 28
Carcinoma of Lung 12 69
Lung Neoplasms 24 69
Lung Neoplasm 12 72
Nsclc 12 51
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 53
Nonsmall Cell Lung Cancer, Susceptibility to 53
Primary Malignant Neoplasm of Lung 69
Bronchioloalveolar Adenocarcinoma 69
Adenocarcinoma of Lung, Somatic 53
Lung Cancer, Susceptibility to 53
Carcinoma, Non-Small-Cell Lung 41
Carcinoma Non-Small Cell Lung 51
Lung Cancer, Resistance to 53
Malignant Tumor of Lung 24
Adenocarcinoma of Lung 71
Lung Malignant Tumors 24
Respiratory Carcinoma 24
Lung Cancer, Somatic 53
Malignant Lung Tumor 24
Neoplasm of the Lung 28
Pulmonary Carcinoma 24
Pulmonary Neoplasms 24
Cancer of Bronchus 24
Cancer of the Lung 24
Lung Malignancies 24
Pulmonary Cancer 24
Neoplasm of Lung 28
Cancer of Lung 12
Cancer Lung 51
Lncr 71

Characteristics:

OMIM:

53
Inheritance:
autosomal recessive


HPO:

31
lung cancer:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Lung Cancer

MedlinePlus : 40 Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk. Common symptoms of lung cancer include A cough that doesn't go away and gets worse over time Constant chest pain Coughing up blood Shortness of breath, wheezing, or hoarseness Repeated problems with pneumonia or bronchitis Swelling of the neck and face Loss of appetite or weight loss Fatigue Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Lung Cancer, also known as non-small cell lung carcinoma, is related to lung cancer susceptibility 3 and lung squamous cell carcinoma, and has symptoms including alveolar cell carcinoma, snoring and coughing. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Non-small cell lung cancer and MicroRNAs in cancer. The drugs Abraxane and Alimta have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are Decreased viability and Decreased viability

OMIM : 53 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). (211980)

UniProtKB/Swiss-Prot : 71 Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

CDC : 3 Lung cancer is the leading cause of cancer death and the second most common cancer among both men and women in the United States.

Genetics Home Reference : 24 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.

Disease Ontology : 12 A respiratory system cancer that is located in the lung.

Wikipedia : 72 Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell... more...

Related Diseases for Lung Cancer

Diseases in the Lung Cancer family:

Lung Benign Neoplasm Lung Carcinoma in Situ

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 639)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 35.0 BRAF CASP8 EGFR ERBB2 HRAS KRAS
2 lung squamous cell carcinoma 34.2 BRAF EGFR HRAS KRAS PIK3CA
3 lung benign neoplasm 33.7 EGFR HRAS KRAS RAF1
4 lung adenoid cystic carcinoma 33.6 DDR2 EGFR HRAS KRAS PIK3CA
5 tumor suppressor gene on chromosome 11 33.4 BRAF DDR2 EGFR ERBB2 IRF1 KRAS
6 adenosquamous cell lung carcinoma 33.0 DDR2 EGFR ERBB2 HRAS KRAS PIK3CA
7 adenocarcinoma 32.4 BRAF EGFR ERBB2 HRAS KRAS RAF1
8 colorectal cancer 32.1 BRAF CASP8 EGFR ERBB2 FASLG HRAS
9 squamous cell carcinoma 32.0 BRAF DDR2 EGFR ERBB2 HRAS PTEN
10 gastric cancer 31.8 EGFR ERBB2 FASLG HRAS IRF1 KRAS
11 esophageal cancer 31.5 EGFR ERBB2 FASLG HRAS KRAS PIK3CA
12 prostate cancer 31.5 CASP8 EGFR ERBB2 HRAS KRAS MAP2K1
13 glioblastoma 31.4 BRAF EGFR ERBB2 HRAS PIK3CA PTEN
14 pancreatic cancer 31.3 CASP8 EGFR ERBB2 HRAS KRAS MAP2K1
15 ovarian cancer 31.3 BRAF CASP8 EGFR ERBB2 FASLG KRAS
16 ovarian cancer 1 31.1 EGFR ERBB2 HRAS KRAS PIK3CA PTEN
17 hepatocellular carcinoma 31.1 CASP8 EGFR FASLG HRAS KRAS MAP2K1
18 thyroid cancer 31.0 BRAF HRAS KRAS MAP2K1 PIK3CA PTEN
19 squamous cell carcinoma, head and neck 30.9 EGFR ERBB2 HRAS PIK3CA PTEN
20 paronychia 30.8 EGFR HRAS KRAS
21 suppression of tumorigenicity 12 30.7 BRAF HRAS PTEN
22 estrogen-receptor positive breast cancer 30.7 EGFR ERBB2 PIK3CA
23 cervical cancer 30.6 CASP8 HRAS PIK3CA PPP2R1B
24 gastric adenocarcinoma 30.6 ERBB2 FASLG HRAS RAF1
25 lung cancer susceptibility 1 12.2
26 lung cancer susceptibility 5 12.1
27 small cell cancer of the lung 12.1
28 lung cancer susceptibility 4 12.0
29 hilar lung neoplasm 11.9
30 non-small cell lung cancer, childhood 11.9
31 small cell lung cancer, childhood 11.9
32 small cell lung cancer, adult 11.9
33 smoking as a quantitative trait locus 3 11.4
34 lambert-eaton myasthenic syndrome 11.4
35 endometrial cancer 11.3 BRAF EGFR ERBB2 HRAS KRAS PIK3CA
36 female reproductive organ cancer 11.3 EGFR ERBB2 HRAS KRAS PIK3CA PTEN
37 gastrointestinal system cancer 11.3 EGFR ERBB2 HRAS KRAS PIK3CA PTEN
38 glioblastoma multiforme 11.3 BRAF EGFR ERBB2 HRAS PIK3CA PTEN
39 acneiform dermatitis 11.2 EGFR ERBB2 HRAS KRAS MAP2K1 PIK3CA
40 cell type cancer 11.2 EGFR ERBB2 HRAS KRAS PTEN
41 paraneoplastic cerebellar degeneration 11.2
42 small intestinal adenocarcinoma 11.2 BRAF EGFR ERBB2 KRAS
43 pilocytic astrocytoma 11.2 BRAF HRAS KRAS PTEN RAF1
44 endometrial adenocarcinoma 11.2 EGFR ERBB2 KRAS PTEN
45 uterine carcinosarcoma 11.2 EGFR ERBB2 HRAS PIK3CA
46 salivary gland cancer 11.1 CASP8 EGFR ERBB2 PTEN
47 exanthem 11.1 EGFR ERBB2 HRAS KRAS
48 lung disease 11.1
49 asbestosis 11.1
50 malignant ovarian surface epithelial-stromal neoplasm 11.1 ERBB2 HRAS KRAS PIK3CA

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to Lung Cancer

Symptoms & Phenotypes for Lung Cancer

Symptoms via clinical synopsis from OMIM:

53
Lung:
alveolar cell carcinoma
non-small-cell cancer


Clinical features from OMIM:

211980

Human phenotypes related to Lung Cancer:

31
# Description HPO Frequency HPO Source Accession
1 alveolar cell carcinoma 31 HP:0006519

UMLS symptoms related to Lung Cancer:


snoring, coughing, hemoptysis, fever, dyspnea

GenomeRNAi Phenotypes related to Lung Cancer according to GeneCards Suite gene sharing:

25 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.09 BRAF HRAS KRAS EGFR PIK3CA
2 Decreased viability GR00106-A-0 11.09 KRAS
3 Decreased viability GR00221-A-1 11.09 DDR2 HRAS KRAS EGFR RAF1 PIK3CA
4 Decreased viability GR00221-A-2 11.09 DDR2 HRAS KRAS MAP3K8 RAF1 PIK3CA
5 Decreased viability GR00221-A-3 11.09 HRAS MAP3K8 ERBB2
6 Decreased viability GR00221-A-4 11.09 BRAF DDR2 EGFR MAP3K8 PIK3CA ERBB2
7 Decreased viability GR00231-A 11.09 RAF1
8 Decreased viability GR00301-A 11.09 BRAF RAF1 KRAS MAP3K8
9 Decreased viability GR00342-S-1 11.09 MAP3K8
10 Decreased viability GR00342-S-2 11.09 MAP3K8
11 Decreased viability GR00342-S-3 11.09 MAP3K8
12 Decreased viability GR00381-A-1 11.09 KRAS BRAF
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.41 ERCC6
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.41 ERCC6
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 10.41 MXRA5
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 10.41 MXRA5
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-167 10.41 CYP2A6
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 10.41 CASP8
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.41 MXRA5
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 10.41 ERCC6
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.41 ERCC6
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-209 10.41 ERCC6
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.41 ERCC6
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.41 CYP2A6
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.41 MXRA5
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 10.41 EGFR
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.41 CASP8
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 10.41 MXRA5
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.41 ERCC6
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.41 CASP8 CYP2A6 EGFR ERCC6 MXRA5
31 Decreased viability in esophageal squamous lineage GR00235-A 10 BRAF DDR2 ERBB2 ERCC6 FASLG HRAS
32 Decreased cell migration GR00055-A-1 9.93 PIK3CA BRAF DDR2 EGFR HRAS KRAS
33 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 EGFR ERBB2 HRAS MAP3K8 PTEN
34 Increased cell death HMECs cells GR00103-A-0 9.63 EGFR IRF1 MAP3K8 PIK3CA PTEN RAF1
35 Decreased cella89culturea89derived Hepatitis C virus (HCVcc GR00234-A-2 9.61 BRAF DDR2 EGFR
36 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 PRKN PTEN RAF1 SLC22A18 CASP8
37 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 FASLG PRKN PTEN RAF1 SLC22A18 BRAF
38 Increased cell migration GR00055-A-3 9.43 HRAS KRAS PIK3CA BRAF DDR2 EGFR

MGI Mouse Phenotypes related to Lung Cancer:

43 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.49 DDR2 EGFR ERBB2 FASLG HRAS IRF1
2 cellular MP:0005384 10.48 BRAF CASP8 DDR2 EGFR ERBB2 ERCC6
3 homeostasis/metabolism MP:0005376 10.44 BRAF CASP8 DDR2 EGFR ERBB2 ERCC6
4 growth/size/body region MP:0005378 10.41 BRAF CASP8 DDR2 EGFR ERBB2 ERCC6
5 endocrine/exocrine gland MP:0005379 10.39 BRAF CASP8 DDR2 EGFR ERBB2 FASLG
6 integument MP:0010771 10.39 BRAF CASP8 DDR2 EGFR ERBB2 ERCC6
7 mortality/aging MP:0010768 10.38 FASLG HRAS IRF1 KRAS MAP2K1 MAP3K8
8 neoplasm MP:0002006 10.31 EGFR ERBB2 ERCC6 FASLG HRAS IRF1
9 immune system MP:0005387 10.3 ERCC6 FASLG IRF1 KRAS BRAF CASP8
10 hematopoietic system MP:0005397 10.29 BRAF CASP8 EGFR ERCC6 FASLG IRF1
11 nervous system MP:0003631 10.28 HRAS KRAS MAP2K1 MAP3K8 PIK3CA PRKN
12 digestive/alimentary MP:0005381 10.24 ERBB2 FASLG HRAS KRAS MAP2K1 MAP3K8
13 embryo MP:0005380 10.24 ERBB2 KRAS MAP2K1 PIK3CA PTEN RAF1
14 craniofacial MP:0005382 10.2 BRAF DDR2 EGFR ERBB2 HRAS KRAS
15 muscle MP:0005369 10.2 RAF1 ERCC6 KRAS PIK3CA PRKN PTEN
16 normal MP:0002873 10.11 PTEN RAF1 BRAF EGFR ERBB2 FASLG
17 liver/biliary system MP:0005370 10.1 BRAF CASP8 EGFR ERCC6 FASLG KRAS
18 hearing/vestibular/ear MP:0005377 10.03 BRAF EGFR ERCC6 KRAS MAP2K1 RAF1
19 reproductive system MP:0005389 9.96 BRAF DDR2 EGFR ERBB2 FASLG KRAS
20 renal/urinary system MP:0005367 9.92 BRAF CASP8 EGFR FASLG HRAS IRF1
21 respiratory system MP:0005388 9.85 BRAF CASP8 EGFR ERBB2 FASLG HRAS
22 skeleton MP:0005390 9.8 PRKN PTEN RAF1 BRAF DDR2 EGFR
23 vision/eye MP:0005391 9.32 BRAF DDR2 EGFR ERCC6 FASLG KRAS

Drugs & Therapeutics for Lung Cancer

FDA approved drugs:

(show all 23)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 45 PACLITAXEL Celgene October 2012
2
Alimta 17 45 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
3
Avastin 17 45 BEVACIZUMAB Genentech July 2009
4
Cyramza 17 45 RAMUCIRUMAB Eli Lilly April 2014
5
Gemzar 17 45 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
6
Gilotrif 17 45 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
7
Hycamtin 17 45 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
8
Iressa 17 45 GEFITINIB AstraZeneca May 2003
9
Keytruda 17 45 PEMBROLIZUMAB Merck September 2014
10
Neutroval 17 tbo-filgrastim Teva Pharmaceutical August 2012
11
Opdivo 17 45 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
12
Photodynamic Therapy (& Photofrin) 17 PORFIMER SODIUM Sanofi-aventis January, 1996
13
Photofrin 17 PORFIMER SODIUM QLT January 1998
14
Tarceva 17 45 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
15
Taxol 17 45 PACLITAXEL Bristol-Myers Squibb August 1997
16
Taxotere 17 45 DOCETAXEL Rhone Poulenc Rorer May 1996
17
Xalkori 17 45 CRIZOTINIB Pfizer August of 2011
18
Xgeva 17 45 DENOSUMAB Amgen June 2013/ November 2010
19
Zometa 17 45 ZOLEDRONIC ACID Novartis August 2001/ February 2002
20
Zykadia 17 45 CERITINIB Novartis April 2014
21
Alecensa 17 ALECTINIB HYDROCHLORIDE Roche December 2015
22
Portazza 17 NECITUMUMAB Eli Lilly November 2015
23
Tagrisso 17 OSIMERTINIB MESYLATE AstraZeneca November 2015

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 936)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 2,Phase 3,Phase 1 51333-22-3 5281004 63006
2
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
3
Terbutaline Approved Phase 4 23031-25-6 5403
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 2767 441203 84093
5
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 150399-23-8, 137281-23-3 60843 446556
7
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
8
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
9
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
10
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 38904 498142
11
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
12
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
13
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
14
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
15 Racepinephrine Approved Phase 4,Phase 2,Phase 1,Early Phase 1 329-65-7
16
Remifentanil Approved Phase 4 132875-61-7 60815
17
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
18
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
19
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6 46507594 772
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 437-38-7 3345
21
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 71486-22-1 44424639 60780
22
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
23
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
24
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
25
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
26
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
27
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
28
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 137-58-6 3676
29
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 2078-54-8 4943
30
Nedaplatin Approved, Investigational Phase 4,Phase 3,Phase 2 95734-82-0
31
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
32
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 38396-39-3, 2180-92-9 2474
33
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
34
Amifostine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 20537-88-6 2141
35
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 89594 942
36
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
37
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
38
Ropivacaine Approved Phase 4,Phase 2 84057-95-4 175805 71273
39
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2 170729-80-3 6918365 151165
40
Fosaprepitant Approved Phase 4,Phase 3,Phase 2 172673-20-0 219090
41
Ondansetron Approved Phase 4,Phase 3,Phase 1,Phase 2 99614-02-5 4595
42
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
43
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
44
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2 57-27-2 5288826
45
Armodafinil Approved, Investigational Phase 4,Phase 1,Phase 2 112111-43-0
46
Modafinil Approved, Investigational Phase 4,Phase 1,Phase 2 68693-11-8 4236
47
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
48
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34911-55-2, 34841-39-9 444
49
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
50
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 6434)

# Name Status NCT ID Phase Drugs
1 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
2 Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
3 Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
4 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
5 PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC) Unknown status NCT00173524 Phase 4
6 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
7 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
8 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
9 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
10 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
11 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
12 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
13 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
14 Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients Unknown status NCT02275702 Phase 4 Dexamethasone IV;Saline solution
15 Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
16 Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
17 First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Unknown status NCT01646450 Phase 4 Icotinib
18 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
19 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
20 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
21 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
22 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
23 Effects of Methylprednisolone on Immunological Function and Postoperative Adverse Reaction in Patients With Lung Cancer Completed NCT03393949 Phase 4 Methylprednisolone 1 mg•kg-1;Methylprednisolone 0.5mg•kg-1
24 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
25 Fentanyl Matrix in Lung Cancer Pain Completed NCT01060137 Phase 4 fentanyl matrix
26 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
27 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4 erlotinib [Tarceva]
28 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
29 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4 zoledronic acid
30 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
31 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed NCT01230710 Phase 4 Erlotinib
32 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
33 Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
34 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed NCT00770588 Phase 4 Gefitinib;Placebo
35 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
36 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Completed NCT00684385 Phase 4 ZD1839
37 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
38 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
39 An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00949910 Phase 4 Erlotinib
40 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
41 A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) Completed NCT00388206 Phase 4
42 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
43 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
44 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
45 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
46 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation Completed NCT02208843 Phase 4 Afatinib
47 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4 Modafinil;Placebo
48 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
49 Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Completed NCT02000531 Phase 4 Erlotinib;Chemotherapy
50 Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: carcinoma, non-small-cell lung

Genetic Tests for Lung Cancer

Genetic tests related to Lung Cancer:

# Genetic test Affiliating Genes
1 Non-Small Cell Lung Cancer 28
2 Lung Cancer 28 BRAF CASP8 CYP2A6 DLEC1 EGFR ERBB2 ERCC6 FASLG IRF1 KRAS MAP3K8 PIK3CA PPP2R1B PRKN RASSF1 SLC22A18
3 Lung Cancer, Protection Against 28
4 Neoplasm of Lung 28
5 Neoplasm of the Lung 28
6 Alveolar Cell Carcinoma 28

Anatomical Context for Lung Cancer

MalaCards organs/tissues related to Lung Cancer:

38
Lung, Brain, Breast, Testes, Bone, Endothelial, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Cancer:

18
The Lung

Publications for Lung Cancer

Articles related to Lung Cancer:

(show top 50) (show all 14134)
# Title Authors Year
1
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. ( 29101033 )
2018
2
Bronchiolitis obliterans organizing pneumonia after stereotactic ablative radiation therapy for lung cancer: A case report. ( 29395853 )
2018
3
Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer. ( 29277824 )
2018
4
miR-455-3p serves as prognostic factor and regulates the proliferation and migration of non-small cell lung cancer through targeting HOXB5. ( 29170127 )
2018
5
EGFR and Ras regulate DDX59 during lung cancer development. ( 29133145 )
2018
6
Effects of siRNA Silencing of TUG1 and LCAL6 Long Non-coding RNAs on Patient-derived Xenograft of Non-small Cell Lung Cancer. ( 29277771 )
2018
7
Carvacrol Targets AXL to Inhibit Cell Proliferation and Migration in Non-small Cell Lung Cancer Cells. ( 29277784 )
2018
8
Risk Stratification According to the Prognostic Nutritional Index for Predicting Postoperative Complications After Lung Cancer Surgery. ( 29450756 )
2018
9
Cav-1 promote lung cancer cell proliferation and invasion through lncRNA HOTAIR. ( 29080835 )
2018
10
Effects of MALAT1 on proliferation and apo- ptosis of human non-small cell lung cancer A549 cells in vitro and tumor xenograft growth in vivo by modulating autophagy. ( 29439314 )
2018
11
How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. ( 29290269 )
2018
12
Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer. ( 29452091 )
2018
13
Survival Impact of Stations of Pathological Lymph Nodes in N2 Non-small Cell Lung Cancer in a French Hospital. ( 29450750 )
2018
14
Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth. ( 29449529 )
2018
15
Pulmonary aspergilloma mimicking synchronous lung cancer on PET/CT in a patient with head and neck cancer. ( 29361322 )
2018
16
Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer. ( 29384034 )
2018
17
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. ( 29406396 )
2018
18
Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer. ( 29450713 )
2018
19
Implementation of Digital Awareness Strategies to Engage Patients and Providers in a Lung Cancer Screening Program: Retrospective Study. ( 29449199 )
2018
20
Small-cell Lung Cancer Associated with SAPHO Syndrome. ( 29033438 )
2018
21
Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report. ( 29402438 )
2018
22
Pulmonary actinomycosis masquerading as lung cancer: keep it in mind. ( 29423982 )
2018
23
The membrane bile acid receptor TGR5 drives cell growth and migration via activation of the JAK2/STAT3 signaling pathway inA non-small cell lung cancer. ( 29074425 )
2018
24
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer. ( 29449326 )
2018
25
MiR-182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene. ( 28940757 )
2018
26
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. ( 29451020 )
2018
27
The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes in Taiwan Lung Cancer Risk. ( 29277780 )
2018
28
KIAA0247 inhibits growth, migration, invasion of non-small-cell lung cancer through regulating the Notch pathway. ( 29451718 )
2018
29
Features of Chronic Obstructive Pulmonary Disease as Predictors of Lung Cancer. ( 29452098 )
2018
30
The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. ( 29452146 )
2018
31
Polysaccharide Functionalized Single Walled Carbon Nanotubes as Nanocarriers for Delivery of Curcumin in Lung Cancer Cells. ( 29448627 )
2018
32
Current Practice of Whole Brain Radiotherapy in Metastatic Non-small Cell Lung Cancer. ( 29449056 )
2018
33
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. ( 29451696 )
2018
34
CD103<sup>+</sup>CD8<sup>+</sup>T lymphocytes in non-small cell lung cancer are phenotypically and functionally primed to respond to PD-1 blockade. ( 29448979 )
2018
35
miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer. ( 29107102 )
2018
36
Real-life experience of ceritinib in crizotinib-pretreated<i>ALK</i><sup>+</sup>advanced non-small cell lung cancer patients. ( 29450203 )
2018
37
p0071 interacts with E-cadherin in the cytoplasm so as to promote the invasion and metastasis of non-small cell lung cancer. ( 28898462 )
2018
38
Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer. ( 29277823 )
2018
39
Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry. ( 29451745 )
2018
40
Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature. ( 29441072 )
2018
41
Combined pulmonary fibrosis and emphysema predicts recurrence following surgery in patients with stage I non-small cell lung cancer. ( 29411159 )
2018
42
Consolidation/Tumor Ratio on Chest Computed Tomography as Predictor of Postoperative Nodal Upstaging in Clinical T1N0 Lung Cancer. ( 29450699 )
2018
43
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. ( 28838388 )
2017
44
Emodin induces apoptosis of lung cancer cells through ER stress and the TRIB3/NF-I_B pathway. ( 28184934 )
2017
45
Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients. ( 28745320 )
2017
46
Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient. ( 29067858 )
2017
47
Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer. ( 28076844 )
2017
48
Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. ( 28903458 )
2017
49
Novel tetrahydroacridine and cyclopentaquinoline derivatives with fluorobenzoic acid moiety induce cell cycle arrest and apoptosis in lung cancer cells by activation of DNA damage signaling. ( 28351316 )
2017
50
Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway. ( 28459375 )
2017